High expression of class III β‑tubulin in small cell lung carcinoma

Powell,Steven; Kaizer,Alex; Koopmeiners,Joseph S.; Iwamoto,Carlos; Klein,Mark

doi:10.3892/ol.2013.1734

High expression of class III β‑tubulin in small cell lung carcinoma

Authors:
- Steven Powell
- Alex Kaizer
- Joseph S. Koopmeiners
- Carlos Iwamoto
- Mark Klein
View Affiliations

Affiliations: Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55418, USA, Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN 55418, USA, Department of Pathology, Minneapolis VA Healthcare System, Minneapolis, MN 55417, USA
Published online on: December 6, 2013 https://doi.org/10.3892/ol.2013.1734
Pages: 405-410

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Class III β‑tubulin (TUBB3) is emerging as a biomarker in a number of cancers. TUBB3 has been shown to be a prognostic indicator of more aggressive disease and a predictor of resistance to taxanes and vinca alkaloids. To date, there is little data on TUBB3 expression in small cell lung carcinoma (SCLC). The primary objective of this study was to determine the expression of TUBB3 in SCLC. Immunohistochemical staining of SCLC tumor specimens was performed using standard procedures. Expression of TUBB3 was determined as a composite of the percentage of malignant cells staining positive and the intensity of staining. Clinical and tumor data for each patient was compared with the degree of TUBB3 expression. A total of 66 SCLCs were evaluable for TUBB3 expression. The majority of specimens (n=56, 85%) had high expression of TUBB3. Only 4.5% (n=3) had low expression of TUBB3. The mean distribution of positive staining for the specimens was 87.3±1.8% (mean ± SE). Specimens from core biopsies were significantly more likely to have high TUBB3 expression when compared with fine needle aspirates (P=0.004). There were no other significant findings when comparing clinical or tumor characteristics. Overall, we found that expression of TUBB3 in SCLC is higher than expected. Innate resistance to microtubule inhibitors, such as the taxanes and vinca alkaloids, may be associated with this finding. Attempts at microtubule inhibition with novel agents may be able to overcome this resistance mechanism. Further evaluation of TUBB3 as a biomarker in SCLC is warranted.

View Figures

View References

1	Argiris A and Murren JR: Staging and clinical prognostic factors for small-cell lung cancer. Cancer J. 7:437–447. 2001.PubMed/NCBI
2	Chute JP, Chen T, Feigal E, Simon R and Johnson BE: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 17:1794–1801. 1999.PubMed/NCBI
3	Smyth JF: Chemotherapy of small cell lung cancer. Chest. 96(Suppl 1): 61S–62S. 1989. View Article : Google Scholar : PubMed/NCBI
4	Katsetos CD, Legido A, Perentes E and Mörk SJ: Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol. 18:851–866. 2003. View Article : Google Scholar
5	Burkhart CA, Kavallaris M and Horwitz SB: The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta. 1471:1–9. 2001.PubMed/NCBI
6	Bernard-Marty C, Treilleux I, Dumontet C, et al: Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer. 3:341–345. 2002. View Article : Google Scholar
7	Ohishi Y, Oda Y, Basaki Y, et al: Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol. 105:586–592. 2007. View Article : Google Scholar : PubMed/NCBI
8	Koh Y, Kim TM, Jeon YK, et al: Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol. 20:1414–1419. 2009. View Article : Google Scholar : PubMed/NCBI
9	Sève P, Reiman T, Lai R, et al: Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol. 60:27–34. 2007.PubMed/NCBI
10	Sève P and Dumontet C: Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9:168–175. 2008.PubMed/NCBI
11	Sève P, Lai R, Ding K, et al: Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res. 13:994–999. 2007.PubMed/NCBI
12	Dumontet C, Isaac S, Souquet PJ, et al: Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer. 92:E25–E30. 2005.PubMed/NCBI
13	Rosell R, Scagliotti G, Danenberg KD, et al: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene. 22:3548–3553. 2003. View Article : Google Scholar : PubMed/NCBI
14	Sève P, Isaac S, Trédan O, et al: Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res. 11:5481–5486. 2005.
15	Sève P, Mackey J, Isaac S, et al: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther. 4:2001–2007. 2005.
16	Katsetos CD, Kontogeorgos G, Geddes JF, et al: Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med. 124:535–544. 2000.PubMed/NCBI
17	Zelen M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3. 4:31–42. 1973.PubMed/NCBI
18	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
19	Urano N, Fujiwara Y, Doki Y, et al: Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol. 28:375–381. 2006.
20	Leandro-García LJ, Leskelä S, Landa I, et al: Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken). 67:214–23. 2010.PubMed/NCBI
21	Raspaglio G, Filippetti F, Prislei S, et al: Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3′ flanking region. Gene. 409:100–108. 2008.PubMed/NCBI
22	Levallet G, Bergot E, Antoine M, et al: High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther. 11:1203–1213. 2012. View Article : Google Scholar
23	Pentheroudakis G, Batistatou A, Kalogeras KT, et al: Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat. 127:179–193. 2011.
24	Ettinger DS, Finkelstein DM, Sarma RP and Johnson DH: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 13:1430–1435. 1995.
25	Kirschling RJ, Grill JP, Marks RS, et al: Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol. 22:517–522. 1999. View Article : Google Scholar
26	Graziano SL, Herndon JE II, Socinski MA, et al: Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol. 3:158–162. 2008. View Article : Google Scholar : PubMed/NCBI
27	Thomas P, Castelnau O, Paillotin D, et al: Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study. J Clin Oncol. 19:1320–1325. 2001.PubMed/NCBI
28	Stinchcombe TE, Mauer AM, Hodgson LD, et al: Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. J Thorac Oncol. 3:1301–1307. 2008. View Article : Google Scholar : PubMed/NCBI
29	Evans WK, Shepherd FA, Feld R, Osoba D, Dang P and Deboer G: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 3:1471–1477. 1985.PubMed/NCBI
30	Smith IE, Evans BD, Gore ME, et al: Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol. 5:185–189. 1987.PubMed/NCBI
31	Rivera E, Lee J and Davies A: Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist. 13:1207–1223. 2008. View Article : Google Scholar : PubMed/NCBI
32	Dumontet C, Jordan MA and Lee FF: Ixabepilone: targeting beta III-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther. 8:17–25. 2009. View Article : Google Scholar